NCT04693507View on ClinicalTrials.gov

Teverelix Evaluated in Advanced Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

December 5, 2022

Study Completion Date

February 6, 2023

Conditions
Prostatic Adenoma
Interventions
DRUG

teverelix TFA 120 mg

Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24

DRUG

teverelix TFA 180 mg

Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24

Trial Locations (4)

LT-50161

Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas

LT-92288

Klaipeda University Hospital, Klaipėda

LT-08660

National Cancer Institute, Vilnius

LT-08661

Vilnius University Hospital Santaros Clinic, Vilnius

All Listed Sponsors
lead

Antev Ltd.

INDUSTRY

NCT04693507 - Teverelix Evaluated in Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter